All proposed resolutions were voted according to management’s recommendations Pr. Michael Caligiuri was appointed as a new member of the Supervisory Board Innate Pharma (Euronext Paris: FR0010331421 –...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2013, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue of 2.7...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for...

Three clinical trials initiated with anti-KIR antibody lirilumab (IPH2102/BMS-986015), including a Phase II trial IPH2201/NN8765 Phase I clinical trial enrolling patients IPH33 drug candidate selected...

Revenue of 14.3 million euros including payments from Bristol-Myers Squibb and research tax credit Strong cash position with 32.6 million euros in cash, cash equivalents and current financial...

A Phase I study of the anti-KIR antibody IPH2102/BMS-986015 in combination with ipilimumab in patients with selected advanced solid tumors published on ClinicalTrials.gov Innate Pharma SA (the...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the first...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, updates on four early clinical...

Revenue of 8.0 million euros Cash position as at September 30, 2012 of 32.3 million euros Change to the supervisory board Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity...